CCDC13

Across TCGA pan-cancer cohorts, CCDC13 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CCDC13 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CCDC13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SARC show a favorable association.

ACC, KIRP, and SCLC are the cancer types where CCDC13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
KIRP	OS	Median	All	0.111	0.702	.001	12	view →
SCLC	OS	Median	All	0.205	0.713	.003	9	view →
COAD	OS	Median	II,III,IV	0.464	0.853	.001	9	view →
LGG	OS	Median	All	0.034	0.909	<.001	6	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →
UCEC	DFS	Median	All	0.967	0.829	.031	6	view →
LUAD	OS	Median	All	0.359	0.700	.022	6	view →
SARC	DFS	Median	All	1.000	0.296	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CCDC13–ACC (DFS)

Open the ACC breakdown →